PURPOSE: Inhibition of Poly (ADP-ribose) Polymerases (PARP) results in the blocking of DNA repair cascades that eventually leads to apoptosis and cancer cell death. PARP inhibitors (PARPi) exhibit their actions either by inhibiting PARP-induced PARylation and/or by trapping PARP at the DNA damage site. But, the mechanism of PARPi-mediated induction of cellular toxicity via PARP-trapping is largely unknown. METHODS: The cellular toxicity of PARPi [Talazoparib (BMN) and/or Olaparib (Ola)] was investigated in oral cancer cells and the underlying mechanism was studied by using in vitro, in silico, and in vivo preclinical model systems. RESULTS: The experimental data suggested that induction of DNA damage is imperative for the optimal effectiveness of PARPi. Curcumin (Cur) exhibited maximum DNA damaging capacity in comparison to Resveratrol and 5-Flurouracil. Combination of BMNâ+âOla induced cell death in Cur pre-treated cells at much lower concentrations than their individual treatments. BMNâ+âOla treatment deregulated the BER cascade, potentiated PARP-trapping, caused cell cycle arrest and apoptosis in Cur pre-treated cells in a much more effective manner than their individual treatments. In silico data indicated the involvement of different amino acid residues which might play important roles in enhancing the BMNâ+âOla-mediated PARP-trapping. Moreover, in vivo mice xenograft data also suggested the BMNâ+âOla-mediated enhancement of apoptotic potentiality of Cur. CONCLUSION: Thus, induction of DNA damage was found to be essential for optimal functioning of PARPi and BMNâ+âOla combination treatment enhanced the apoptotic potentiality of Cur in cancer cells by enhancing the PARP-trapping activity via modulation of BER cascade.
Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
talazoparib 和 olaparib 的联合应用通过 PARP-1 捕获增强了姜黄素介导的口腔癌细胞凋亡
阅读:3
作者:Chatterjee Subhajit, Dhal Ajit Kumar, Paul Subarno, Sinha Saptarshi, Das Biswajit, Dash Somya Ranjan, Kundu Chanakya Nath
| 期刊: | Journal of Cancer Research and Clinical Oncology | 影响因子: | 2.800 |
| 时间: | 2022 | 起止号: | 2022 Dec;148(12):3521-3535 |
| doi: | 10.1007/s00432-022-04269-7 | 研究方向: | 细胞生物学 |
特别声明
1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。
4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。
